Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

NCT00467610 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped lack of efficacy.

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Panhematin

Sponsor

Rush University Medical Center

Collaborators

[object Object]